

This is author version of article published as:

Yarlagadda, Prasad K. and Chandrasekharan, Margam and Shyan, John Yong Ming (2005) Recent advances and current developments in tissue scaffolding. *Bio-Medical Materials and Engineering* 15(3):pp. 159-177.

Copyright 2005 IOS Press

Recent Advances and Current Developments in Tissue Scaffolding

***Prasad KDV Yarlagadda**, *Margam Chandrasekharan*[@] and *John Yong Ming Shyan*[@]**

* School of Mechanical, Manufacturing and Medical Engineering, Queensland University of Technology, Brisbane, Australia

[@] Forming Technology, Singapore Institute of Manufacturing Technology, 71, Nanyang Drive, Singapore 638075

Abstract:

A bio-scaffold can be broadly termed as a structure used to substitute an organ either permanently or temporarily to restore functionality. The material that can be used varies with the application intended. Tissue Engineering is one such application demanding certain requirements to be met before it is applied. One of the applications in tissue engineering is the tissue scaffold, which provides either a permanent or temporary support to the damaged tissues/organ until the functionalities are restored. A biomaterial can exhibit specific interactions with cells that will lead to stereotyped responses. The use of a particular material and morphology depends on various factors such as Osteoinduction, Osteoconduction, angiogenesis, growth rates of cells and degradation rate of the material in case of temporary scaffolds etc. The current work reviews the state of art in tissue scaffolds and focuses on permanent scaffold materials and applications with a brief overview of temporary scaffold materials and their disadvantages.

1. Introduction and Background

The application of material in the field of medicine started as early as 17th century where wood was used to make artificial legs for restoring functionality of the legs. However, it was only during the last four decades the use of materials in medicine gained attention [119]. A significant development in the use of artificial materials in medicine was the Charnley's low friction arthroplasty [124]. The use of artificial materials often posed problems such as inflammatory response of surrounding tissues, need for secondary/revisional surgical procedure due to premature failure of the implants, stress shielding effects on the natural bone etc. The problems associated with the artificial organs directed research towards developing

materials/methods to restore functionality of organs with the assistance of minimally invasive surgical procedures. Tissue engineering is a multidisciplinary subject combining the principles of engineering, biology and chemistry to restore the functionality of damaged tissue/organ through repair or regeneration. The material used in tissue engineering or as a tissue scaffold can either be naturally derived or synthetic. Further classification can be made based on the nature of application such as permanent or temporary. A temporary structure is expected to provide the necessary support and assist in cell/tissue growth until the tissue/cell regains original shape and strength. These types of scaffolds are useful especially in case of young patients where the growth rates of tissues are higher and the use of an artificial organ to restore functionality is not desired. However, in case of older patients, temporary scaffolds fail to meet the requirements in most cases. These include poor mechanical strength, mismatch between the growth rate of tissues and the degradation rate of the said scaffold. Thus the older patients need to have a stronger scaffold, which can either be permanent or have a very low degradation rate. Due to the contrasting nature of requirements posed a judicial compromise between the properties requirement and the degradation rate has to be arrived at for the use of scaffolds in elderly patients [139]. Most of the works on scaffolding has been done on temporary scaffolds owing to the immediate advantages realized of the materials used and the ease of processing. Despite early success, tissue engineers have faced challenges in repairing/replacing tissues that serve predominantly biomechanical roles in the body. In fact, the properties of these tissues are critical to their proper function *in vivo*. In order for tissue engineers to effectively replace these load-bearing structures, they must address a number of significant questions on the interactions of engineered constructs with mechanical forces both *in vivo* and *in vitro* [1].

Once implanted in the body, engineered constructs of cells and matrices will be subjected to a complex biomechanical environment, consisting of time-varying changes in stresses, strains, fluid pressure, fluid flow and cellular deformation behavior [2]. It is now well accepted that these various physical factors have the capability to influence the biological activity of normal tissues and therefore may play an important role in the success or failure of engineered grafts [3,4]. In this regard, it would be important to better characterize the diverse array of physical signals that engineered cells may experience *in vivo* as well as their biological response to such potential stimuli. This information may provide an insight into the long-term capabilities of engineered constructs to maintain the proper cellular phenotype [5]. This paper attempts to present a brief over view on the tissue scaffolds both temporary and permanent, their processing and the present trends in scaffolding techniques.

2. Initial Applications of Tissue Scaffolding in Artificial organs

As explained above the tissue engineering or scaffold engineering techniques started with the use of artificial implants to restore functionality of damaged organ. The use of artificial implants started as early as the 17th century. Romans used legs made of wood to replace damaged legs/limbs to restore functionality. Thereafter the developments in the area of artificial implants were slow until 1962 when Charnley used low friction arthroplasty with Polytetra Fluoroethylene (PTFE) to replace damaged joints. Subsequently, significant advances were made over the last four decades in the use of artificial implants. Various materials ranging metallic, ceramic and polymeric materials were used in artificial implants especially in the field of orthopedics. Stainless steel (surgical grade) was widely used in orthopedics and dentistry applications owing to its corrosion resistance. However later developments included the use of Co-Cr and Ti alloys owing to biocompatibility issues and bio inertness. Currently Ti alloys and Co-Cr alloys are the most widely used in joint prostheses and other biomedical applications such as dentistry and cardio-vascular applications. Despite the advantages of materials such as Ti and Co-Cr and their alloys in terms of biocompatibility and bio inertness, reports indicated failure due to wear and wear assisted corrosion. Ceramics was a good alternative to metallic implants but they too had their limitation in their usage. One of the biggest disadvantages of using metals and ceramics in implants was the difference in modulus compared to the natural bone. (The modulus of articular cartilage varies from 0.001-0.1 GPa while that of hard bone varies from 7-30 GPa). Typical modulus values of the most of the ceramic and metallic implants used lies above 70 GPa. This results in stress shielding effect on bones and tissues which otherwise is useful in keeping the tissue/bone functional [143]. Moreover rejection by the host tissue especially when toxic ions (in the alloy such as Vanadium in Ti alloy) are eluted causes discomfort in patients necessitating revisional operations to be performed. Polymers have modulus within the range of 0.001-0.1 GPa and have been used in medicine for long whose application ranges from artificial implants, i.e., acetabular cup, to drug delivery systems owing to the advantages of being chemically inert, biodegradability and possessing properties, which lies close to the cartilage properties. With the developments in the use of artificial implants there were growing concerns on the biocompatibility of the materials used for artificial implants and the immuno-rejection by the host cells. This led to the research on the repair and regeneration of damaged organs and tissues, which started in 1980 with use of autologous (use of grafts from same species) skin grafts. Thereafter the field of tissue engineering has seen rapid developments from the use of synthetic materials to naturally derived materials that include use of autografts, allografts and xenografts for repair or regeneration of tissues.

3. Trends in tissue engineering Scaffolding

The use of engineered tissues dates back to as early as 1980's and has not matured yet. One of the reasons for its continued development is due to its multidisciplinary nature with varied requirements where it is necessary to combine the fields of engineering, medicine, chemistry and biology to arrive at the right kind of design or material. The primary aim of tissue engineering is to restore functionality of damaged organs/tissues from within the system instead of depending on artificial organs. Despite the early success in the use of Autografts, Allografts and Xenografts, which have good compatibility and recognition by the host tissue, there have been concerns about infection and second site morbidity of such tissues. In addition to the above donor scarcity necessitated further research in the field of Tissue Engineering to develop alternate methods. This called for the use of synthetic/naturally derived materials for scaffolding applications and seed the cells for growing natural tissue. The typical application of tissue engineering extends from human cells, tissues or organs to animal cells, tissues or organs.

The above-mentioned products are in different stages of development. In a little over a decade more than \$3.5 billion is invested in worldwide research and development in tissue engineering. Many of the tissues and organs to be replaced/repared serve important biomechanical functions and despite early successes, tissue engineers have faced challenges in repairing or replacing tissues [6]. Due to their complex nature and composition, most biological tissues can be classified from a material standpoint as inhomogeneous, viscoelastic, nonlinear and anisotropic materials. The fundamental basis for these behaviors is not fully understood, and may differ among different tissues. Also it remains to be determined, which aspects of these mechanical properties are essential for the normal, healthy functioning of different tissues and also for the replacements [7].

Assessment of the outcome of successful functional tissue engineering will require quantitative measures of graft properties, structure and composition. Given the biomechanical nature of many tissue-engineered products, there have been surprisingly few reports of the material or structural properties of engineered tissues. For example, several investigators have reported either mechanical property of grafts prior to implantation [8] or at sacrifice [9, 10]. An important direction in this field will be the development of new methodologies that will allow assessment of the material or structural properties of engineered tissues in a non-invasive or minimally invasive manner.

Hence the ultimate goal is to develop effective substitute or replacements for bone, cartilage, enamel, dentin, cementum and the periodontal ligament. Approaches for achieving this goal will consist of three strategies.

1. Using stem cells and their lineage to regenerate missing or damaged tissue *in vitro* or *in vivo*.
2. Developing new classes of biomaterials that may be either biologically derived or wholly synthetic.
3. Developing innovative physical/chemical stimuli to induce existing adult tissues to regenerate missing or damaged body parts.

It is important for an improved understanding of interfaces between cells, between cells and matrix, between different kinds of matrix and between cells, matrix and minerals. Interfaces between organic-inorganic compounds need to be more thoroughly investigated to determine the environment needed for physiological calcification and to achieve new approaches to designing hard tissues. Improved understanding of factors that affect regeneration and repair of tissues and the effect of nutrients, hormones, age and gender on such factors is needed. This kind of understanding will allow polymeric delivery systems to be developed and will provide new ways of influencing bone cells and other cell types.

Many of the present generation biomaterials are still based upon the early concept that implantable materials should be bioinert and therefore designed to evoke minimal tissue response, if none [11, 12]. However, a growing body of clinical data demonstrates that the long survivability of these materials is hampered by high rates of failure, which is primarily attributed to interfacial instability. Biomaterials developed should actively interact with tissues and thereby induce their repair/regeneration [13]. It is a far-gone conclusion that old cells must die and be replaced [14]. Biomaterials enable the repair and replacement of deteriorated bones and joints [15, 16]. The first generation of biomaterials selected was chemically inert in the body. These include, special medical grades of stainless steel, cobalt-chrome alloys, titanium alloys and polymer materials such as polyethylene and poly-methyl-methacrylate and are still the dominant materials in orthopedic surgery [17]. However such implants are reported to fail before the patient dies [18]. The reason for the failure is the progressive deterioration of the bone in contact with the biomaterial. Many factors contribute to the gradual breakdown of this interface; micromotion, wear debris, infection, stress-shielding etc. [19]. Creating new biomaterials is now the greatest challenges in material science.

4. Current Tissue Scaffold engineering techniques

As defined earlier in this paper scaffolds are constructs, which are used as a temporary support structure allowing the tissues/cells to adhere, proliferate and differentiate to form a healthy bone/tissue for restoring the functionality. The scaffolds can be classified in to two different categories based on their shelf life. The two categories are permanent and temporary implants. Permanent scaffolds those that retain their shape and strength through the process of regeneration/repair of the organ while the temporary scaffolds degrade over a period of time with the regeneration of the organ or tissue. Applications such as oral and maxillofacial surgery rely on the hard permanent scaffolds such as titanium-based scaffold for reconstruction or regeneration of the tissue/organ. However, research has been focused on development of scaffolds, which will be made of biodegradable and bioresorbable materials for most other tissue engineering applications. Temporary scaffolds used in tissue engineering can be broadly divided into two categories; synthetic or naturally derived, with a third category of semi-synthetic materials rapidly emerging. A particular challenge in addressing materials is that the processes are not yet completely understood well enough to allow a clear set of design parameters to be specified *a priori*. Adaptation of already used materials can have some advantages from the regulatory perspective, as the safety and toxicity profiles of the materials in humans are already defined, but other performance aspects such as cell material performance interactions and degradation properties however are not assured. This need for substantially higher performance characteristics is pushing research and development in the design of new materials that meet specific performance criteria in tissue engineering.

The field of biomaterials and scaffolds for tissue engineering is in an adolescent phase and maturing rapidly. One of the most important changes coming in the field is the strong need to integrate basic polymer science and engineering with molecular cell biology and stem cell biology in the design of new materials that carry out very sophisticated signaling needs.

The scaffold structures can be classified as adapted or designed. The structure of a scaffold plays an important role in guiding tissue development. Three very general types of scaffold are structural scaffolds with an imposed pore structure; gelatin type scaffolds formed *in situ* in the presence of cells or tissues, and natural tissue derived gels. For most tissues, the key requirement that can be defined at present is that interconnected porosity of larger dimensions than the cells is required or desired.

A variety of woven and non-woven fibrous fabrics, including plaster of Paris have been developed for tissue engineering purposes. Fibres are used because they present a large surface

area to volume ratio, which supports cell attachment, while creating paths for the rapid diffusion of nutrients for cell survival and growth. Tissue engineered bone; cartilage, heart valves, bladder and liver have been created with non-woven fibre scaffolds using rapid prototyping [20]. Research work is also currently being carried out on woven fibre technology for scaffold engineering using both natural (mostly collagen) and artificial polymer fibres [20]. The limitations of fabrics are lack of structural stability and possibly suboptimal microarchitecture, however this is now being catered for through hybridization in which sponges are combined with fibres to create scaffold [20]. In the case of artificial fibrous scaffold hot-drawing of PLLA fibres have been tried successfully to create structural stability by generating improved molecular orientation and crystallinity [21]. Furthermore, structural stability has been addressed by strengthening the joints of fibrous scaffold meshes with heated PLLA matrix [20,21].

The mechanical properties of degradable synthetic polymers are not always suitable for tissue engineering due to their relative inflexibility and tendency to crumble upon degradation. This has led to development of additional polymers like polyhydroxybutyrate (PHB) and copolymers of hydroxybutyrate with hydroxyvalerate [22]. They are included in this category due to their chemical simplicity and similarity to classical degradable polymers. The acidic degradation products of the classical polyesters Polylactic Acid (PLA), Polyglycolic Acid (PGA), and Polycaprolactone (PCL) and their copolymers have adverse tissue reactions, particularly in bony sites [24]. Hence there is need for improved biomaterials and scaffolds for tissue engineering. Some of the electron microscopy pictures of Collagen scaffolds and Confocal microscope image of PGA scaffolds is shown in Fig.1.

For regeneration of structural tissues, the scaffolds must possess several features that are difficult to achieve using current manufacturing methods [25]. Precise control of porosity and internal pore architecture is necessary to maximize nutrient diffusion, interstitial fluid [26] and blood flow [27], to control cell growth and function [28-31], to manipulate tissue differentiation [32-35], and to optimize scaffold mechanical function [36], and generated tissue mechanical properties [37]. The ability to manufacture with a range of materials is essential to control scaffold degradation and mechanical integrity, cells interaction with scaffold and cell function. To achieve this, a robust fabrication method that allows independent variation of scaffold structural parameters and materials are necessary.

Conventional sponge scaffold manufacturing methods are capable of producing structures with locally porous internal architectures from a diverse array of materials [38]. Local pores are

voids characteristically defined by small struts and plates or spherical and tubular cavities generally less than 300 μm in diameter. Local pores are interconnected within local regions of the scaffold microstructure. For example, porogen leaching yields cavities with defined shape [39-41] while an emulsion leads highly interconnected voids [42]. Solvent diffusion from emulsions can yield oriented pore structures [43,44]. Although these methods yield interconnected pores that may comprise a continuous conduit throughout a scaffold, the pore connectivity is not an intentional result of an *a priori* global design; rather, the connectivity is a random product of variable, local void interconnections that are affected by polymer processing parameters. Such random connections may not provide optimal scaffold permeability for tissue in growth nor optimal connectivity to maximize regenerated tissue mechanical properties [45]. Another problem associated with such highly interconnected pore architecture is the loss of strength and similar properties, which defeats the purpose of the scaffold in few cases.

Micro milling, textile and solid free form fabrication can be used for producing scaffolds with global pores [46, 47]. Global pores are channels with non-random interconnectivity and are generally greater than 100 μm in width. They are designed *a priori* to interconnect on a global scale across the scaffold. Previously, investigators have described scaffold pores based on size as either micro (width < 100 μm) or macro (width > 100 μm) [48, 49]. In contrast, global and local pores are discriminated based upon the extent of designed, not random pore interconnectivity. Zhang et al. [49] fabricated PLA scaffolds that contained stacked two-dimensional (2D) oriented global pores by leaching layered meshes made from drawn sugar fibers. While control over global pore size and 2D orientation was achieved, full control over global pore architecture is not possible without Solid Free Form (SFF) methods. Particularly, fabrication of interpenetrating pore systems that are mutually exclusive and pore channels that branch in three-dimensional (3D) space is impractical. Moreover, fabrication of scaffolds that mimic biological micro-structures is challenging. Such biomimetic scaffolds may prove invaluable to investigate structure-function relationships in living tissues and to replace native tissue function. [25, 51].

SFF scaffold manufacturing methods provide excellent control over scaffold external shape and internal pore interconnectivity and geometry, but offer limited micro-scale resolution. Currently, direct SFF fabrication is capable of producing global pores with a minimum feature size of 100 μm [52]. SFF fabrication, also known as rapid prototyping, consists of manufacturing a 3D part in a layered fashion based on a computer representation. The part is

often post processed (e.g. cleaning, curing, finishing) to yield the final product. During indirect SFF manufacturing, the part is used as a mould to cast the final product. These manufacturing techniques include: (1) fused deposition modeling (FDM of polymers) [53-55], (2) selective laser sintering (SLS) of polymers [56], ceramics [57], metals [58], and composites [59], (3) stereolithography (STL) of polymers and polymer/ceramic slurries [60-62], and (4) direct 3D printing (3DP) of polymers, ceramics [63], metals [64], and polymer ceramic powders [65]. Although the SFF technique has its advantages, the manufacturing processes limit the number of polymeric materials that can be used for direct SFF fabrication. For example, FDM and SLS require thermoplastic polymers, STL necessitates the use of radical initiated polymerization, and 3DP involve the use of solvents and binders. Additionally, direct SFF require multi faceted manufacturing control, including complex correction of scaffold designs for anisotropic shrinkage during fabrication. Incorporation of local pores under direct SFF is difficult because porogens or effusive solvents may interfere with the SFF method.

A group of researchers [140-146] attempted to use Titanium as a scaffold material in tissue engineering for applications demanding high mechanical strength and modulus. However, some of the typical problems indicated earlier such as stress shielding, premature failure due to poor wear properties, higher modulus compared to bone leaving to uneven stress distribution etc are associated with such scaffolds.

Composites of polymers and ceramics are noteworthy because the mixed material composition can confer favorable mechanical properties, including strength via the ceramic phase, toughness and plasticity via the polymer phase and graded mechanical stiffness. Biological advantages include enhanced control over cell differentiation and the potential to deliver multiple bio-factors, including growth factors gene therapy vectors and cells. Composite scaffolds may prove necessary for reconstruction of multi-tissue organs, tissue interfaces and structural tissue including bone, cartilage, tendon, ligament and muscle [66]. Materials in a composite may occupy the same volume as in a blend, occupy different volumes in one structure as in discrete composites, or may be combinations thereof. Composite fabrication research has focussed on developing polymer/ceramic blends, precipitating ceramic onto polymer templates [67-69] and coating polymers onto ceramics [70,71]. hydroxyapatite/poly(L)lactic (HA/PLA) blends have been made by melting and hot/cold pressing [72-75]. Solvent casting [76-79], in situ polymerization [80], and 3D printing. Additionally, sponges made from collagen and calcium phosphates or sintered bovine bone have been made via coating [81], gelation [82], or precipitation [83]. However, the mechanical property requirements for hard tissue repair are difficult to satisfy using blends because large

amounts of ceramic must be incorporated, making fabrication difficult. Kikuchi et al. found PLA must be reinforced with 75-80% HA powder to serve as a bone replacement [83]. Although HA reinforced polymer structures have shown improved strength and higher modulus proportional to increased HA content, the scaffold mechanical properties often become variable at HA concentrations above 70%. Therefore, composites with discrete regions of sintered HA are desirable for bone/soft tissue interfaces.

5. Naturally Derived Materials for Tissue Scaffolding

Lost or damaged genitourinary tissues have been reconstructed with native nonurologic tissues, examples are gastrointestinal segments [100, 101] skin [102], peritoneum [103] fascia [104] omentum, [105], dura or synthetic prostheses like silicone [106], polyvinyl and teflon.

Woven meshes of PGA (Dexon) have been used to reconstruct urethras in dogs. The polymer meshes were completely absorbed after 3 months. However the excised corpus spongiosum was not generated [107].

Collagen is the most abundant and ubiquitous structural protein in the body and may readily be purified from both animal and human tissues with enzyme treatment and salt/acid extraction [108]. Collagen has been known to elicit minimal inflammatory and antigenic responses [109]. This has been approved by the United States Food and Drug Administration (FDA) for many types of medical applications including wound dressing and artificial skin [110]. Collagen implants degrade through a sequential attack by lysosomal enzymes. The *in vivo* resorption rate can be regulated by control of the density of the implant and the extent of intermolecular cross-linking. The lower the density, the greater the interstitial space and generally the larger the pores for cell infiltration leading to a higher rate of implant degradation. Intermolecular cross-linking reduces the degradation rate by making the collagen molecules less susceptible to enzymatic attack [111]. Inter molecular cross-linking can be accomplished by various physical or chemical techniques [112]. Collagen contains cell adhesion domain sequences that elicit specific cellular interactions. This may assist in retention of the phenotype and activity of many types of cells, including fibroblasts [113] and chondrocytes [114]. Collagen exhibits high tensile strength and flexibility and these mechanical properties can be further enhanced by intermolecular cross-linking. This material can be processed into a wide variety of structures like fibers, films etc. Methods for stabilizing collagen-based materials with catechol containing monomers were developed in order to produce fibers with mechanical properties in tension comparable to those of normal tendon.

Alginate, a polysaccharide isolated from seaweed has been used as an injectable cell-delivery vehicle [115] Alginate is biocompatible and has been approved by the FDA for human use as a wound-dressing material. Alginate is a family of copolymers of D-mannuronate and L-glucuronate. The physical and mechanical properties of alginate gel are strongly correlated with the proportion and length of the polyglucuronate block in the alginate chains [115]. However, alginate does not possess a biologic recognition domain. In addition the range of mechanical properties available from alginate hydrogels is quite limited and changes in a uncontrollable manner, presumably due to loss of ionic cross-linking. Recently, efforts were made to synthesize biodegradable alginate hydrogels with mechanical properties controllable in a wide range by intermolecular covalent cross-linking and with cell adhesion peptides coupled to their backbones [116].

Acellular tissue matrices are collagen rich matrices prepared by mechanical and chemical manipulation of a segment of bladder tissue [117]. The matrices slowly degrade upon implantation and are replaced and remodeled by Extra Cellular Matrices (ECM) proteins synthesized and secreted by transplanted or in growing cells. Acellular tissue matrices have been proven to support cell in growth and regeneration of genitourinary tissues, including urethra and bladder tissues, with no evidence of immunogenic rejection [118]. Since the structure of the proteins in acellular matrices are well conserved and normally arranged, the mechanical properties of the acellular matrices are not significantly different from those of native bladder submucosa [119].

The effect of temporary encapsulation of rat marrow stromal osteoblasts in cross-linked gelatin micro particles on cell viability and proliferation was investigated by Gregory et al. [120] for micro particles placed on a cross-linking poly propylene fumarate (PPF) composite over a 7 day time period. Encapsulated cells were seeded on cross-linking PPF composites at times up to 10 min following initiation of the cross-linking reaction, and also on fully cross-linked PPF composites and tissue culture polystyrene controls, with a cell seeding density of 5.3×10^4 cells/cm². The cross-linked PPF composite exhibited an average gel point of 10.3 min and an average maximum cross-linking temperature of 47.5°C. Cell viability and proliferation were assessed by DNA and 3H-thymidine assays and the results were compared with those for non encapsulated cells. The results showed that the addition time of cells to a cross-linking PPF composite had a large effect on cell viability and proliferation for both encapsulated and non encapsulated cells with more surviving time points. The study indicated that the presence of gelatin micro particles does not affect the cross-linking of a PPF composite. They further suggest that the temporary encapsulation of cells in cross-linked gelatin micro particles may

preserve the viability of cells contained in an actively cross-linking PPF composite used as an injectable polymeric scaffold serving also as a carrier for osteogenic cell populations.

Silk from the silkworm, *Bombyx Mori*, has been used as biomedical suture material for centuries. The unique mechanical properties of these fibers provided important clinical repair options for many applications. During the past 20 years, some biocompatibility problems have been reported for silkworm silk; however, contamination from residual sericin (glue-like proteins) was the likely cause. More recent studies with well-defined silkworm silk fibers and films suggest that the core silk fibroin fibers exhibit comparable biocompatibility *in vitro* and *in vivo* with other commonly used biomaterials such as polylactic acid and collagen. Furthermore, the unique mechanical properties of the silk fibers, the diversity of side chain chemistries for 'decoration' with growth and adhesion factors, and the ability to genetically tailor the protein provide additional rationale for the exploration of this family of fibrous proteins for biomaterial applications. For example, in designing scaffolds for tissue engineering these properties are particularly relevant and recent results with bone and ligament formation *in vitro* support the potential role for this biomaterial in future applications. To date, studies with silks to address biomaterial and matrix scaffold needs have focused on silkworm silk. With the diversity of silk-like fibrous proteins from spiders and insects, a range of native or bioengineered variants can be expected for application to a diverse set of clinical needs [121]. Some of the examples of natural and synthetic scaffolds are shown in Fig.2

Hydrogels, cross-linked hydrophilic polymers, represent an important class of biomaterials in biotechnology and medicine because many hydrogels exhibit excellent biocompatibility, causing minimal inflammatory responses, thrombosis and tissue damage [124]. Hydrogels can also swell large quantities of water without the dissolution of the polymer due to their hydrophilic but cross-linked structure, thus giving them physical characteristics similar to soft tissues. In addition, hydrogels have high permeability of oxygen, nutrients, and other water-soluble metabolites. Over the past three decades, a number of hydrogels differing in structure, composition and properties have been developed. These materials are used for biosensors, linings and scaffold devices [125]. Photopolymerized hydrogels have been investigated for a number of biomedical applications like drug delivery [127], coatings for biosensors [128] and for cell transplantation [129-131]. Photopolymerizable hydrogels have been utilized as scaffolds for vascular cell growth. Endothelial cells in biodegradable poly(propylene fumarate-c-ethyleneglycol) scaffolds were implanted subcutaneously Mann et. al. in rats [132]. These materials were PEG-diacrylate derivatives with grafted RGD-peptides. The cells were homogeneously distributed within the scaffolds and remained viable with subsequent

proliferation and matrix protein production. In proteolytically degradable scaffolds, cells were able to spread and migrate, while in non-degradable hydrogels, cells were round and formed clusters. Additionally, cell proliferation and extracellular matrix production reached higher levels in proteolytically degradable hydrogels than in similar non-degradable PEG-diacrylate scaffolds [134].

The study conducted by Masatoshi et al. [134] investigated whether three biodegradable materials, poly-N-acetyl-D-glucosamine (chitin), poly- ϵ -caprolactone (p-CL), polylactic acid (PLA) and chitin/p-CL composite could be used as scaffold implants in the reconstruction of extra-articular ligaments or tendons. With chitin tendons, there was good tissue in growth among the chitin fibers. However, because of the rapid loss of strength *in vivo* and the inability to maintain sufficient strength, chitin cannot be used alone as an artificial tendon. p-CL had stronger load at failure than chitin, but it scarcely induced the formation of new fibrous tissues, so p-CL alone is also unsuitable as an artificial tendon. Conversely, both PLA tendons and the composite chitin/p-CL tendons had good initial strength and showed increased in growth of fibrous tissue, suggesting that these materials are promising as artificial tendons.

6. Bioactive Materials Used in Tissue Engineering.

Bioactive glasses composed of 45 to 52% SiO_2 , 20 to 24% CaO , 20 to 24% Na_2O and 6% P_2O_5 have been successfully used in clinical practice [85-87]. The characteristics of this Class A bioactive materials are good bonding with both bone and soft connective tissues, both osteoproduative (colonization and proliferation of bone distant from and implantation site) [88] and osteoconductive (growth of bone along the surface of the material) [88, 89], and finally the material resorbs as new bone replaces it. A particulate form of the 45S5 composition, called Bioglass has been used to regenerate bone in periodontal defects [90].

Synthetic hydroxyapatite (HA) is an example of a Class B bioactive material. Its characteristics are bonding with bones but not to soft tissues, osteoproduative and it resorbs very slowly if at all in contact with newly forming bones. Osteoconductivity is an essential property of porous hydroxyapatite, which leads to replication of a trabecular bone structure [91]. This characteristic has led to the clinical applications to fill large bone defects. This is sold commercially as “Interpore”.

Until recent experiments by Hench and others [13, 89] little was known about the molecular mechanisms responsible for enhanced bone proliferation and differentiation; i. e. enhanced osteogenesis, stimulated by the presence of Class A bioactive glasses [93]. Previous studies in cell culture established that oestoblasts from various sources grown on 45S5 Bioglass

increased in number and produced more phenotype markers, such as alkaline phosphate, than did equivalent osteoblasts grow on metal substrates such as stainless steel or Ti, plastics or even Class B bioactive materials such as synthetic hydroxyapatite [16, 94-96]. Other cell culture studies of primary human osteoblasts grown in the presence of certain silicate materials, Zeolite A, or either extracts showed an enhanced production of a class of growth factors compared with control materials [97]. Other osteoblast culture studies showed evidence of enhanced extracellular matrix production and even nodule formation in the presence of bioactive glasses [98]. However none of the studies has reported that it is the shift in cell cycle that is responsible for the enhanced osteoblasts are exposed to Class A bioactive materials. Studies by Hench et al., [13, 90] have shown that the bioactive shift of osteoblast cell cycle is under genetic control. It seems that Class A bioactive glasses enhance osteogenesis through a direct control over genes that regulate cell cycle induction and progression. This conclusion provides hope that it will be possible to deliver a critical concentration of the bioactive genetic stimuli to reactivate the osteoprogenitor cells of aging people and prevent or perhaps even reverse the deterioration of bone. If this can be achieved it will be a remarkable innovation in biomaterial research.

7. Scaffolds for Hard Tissue and Bone Reconstructions

Though significant advances have been made in scaffold fabrication for soft tissue replacement using degradable synthetic polymers or natural polymers, hard tissue replacements have posed a potential challenge to biomedical engineers and surgeons. Current practice to repair/regenerate hard tissues is to use autografts. However, due to limitations on the availability, second site morbidity of tissues and patient associated problems alternative treatment methods are being researched on. Strength analysis of osteotomy fixation performed by Marcelo et al [137] indicated that the resorbable systems (polyurethane) possess lower elastic stiffness and modulus compared to permanent Titanium systems. The resorbable systems showed isolated failure for in-vitro testing and despite their ability to withstand the mastication forces in-vitro, the in-vivo behavior is yet to be successfully tested. Though the resorbable systems can be used for scaffolding in soft tissue regeneration, hard tissues necessarily require bone grafting using either autografts or xenografts. An alternative to this is to use hard titanium based implant with a bioactive surface. A typical problem associated with this type of implant is the stress shielding and adverse tissue reactions with the alloying additions used due to micro movements.

Research has also been focused on use of porous Titanium scaffolds for tissue engineering applications [140-146] and induction of bioactivity by using secondary processing such as coatings. This type of porous Titanium scaffolds have received considerable interest in the recent past owing to their advantages over biodegradable matrices such as PLA/PGA and other associated polymeric materials. Titanium and its alloys have been widely used as scaffolds for maxillofacial and craniofacial reconstructions over the past two decades. Besides this Titanium mesh in the form of fenestrated sheets have been used in the acetabular replacement surgery [138]. Titanium meshes were first used by Jurgen harms and Lurtz Biederman in 1986 for spinal surgery forming in to different shapes to support the bony structure [139]. This design was further modified to provide the strength to the construct. The Titanium mesh cage contoured in to cylindrical shape has been used successfully for Anterior Lumbar Interbody fusion for more than 15 years in surgery. Titanium mesh cages were used with autografts for bone grafting in spinal fusion. This is restricted by factors such as complications and second site morbidity. One method to overcome this problem is the use of hydroxyapatite to provide the necessary bioactivity to the Titanium mesh cage with porous network to facilitate osteoconduction. This method has been found to be successful and a viable alternative to autograft or femoral ring allografting methods [140].

8. Surface Architecture and Terrain for Cell Culture for Scaffolding

Surface terrain or topography is one of the important factors governing cell adhesion and proliferation, and there has been many studies carried out in recent research to investigate the suitability of materials such as spider webs and cover slips, fish scales, plasma clots, and glass fibres [135]. Silk fibres have also been used extensively in surgical implant such as suture and artificial blood vessels [136]. Few researchers [135,150-153] studied the applicability of cellulose roughness as a possible texture for tissue scaffold and successfully cultured hepatocytes cells. Cell adhesion to materials is mediated by cell-surface receptors, interacting with cell adhesion proteins bound to the material surface. In aiming to promote receptor mediated cell adhesion the polymer surface should mimic the ECM. ECM proteins, which are known to have the capacity to regulate such cell behaviors as adhesion, spreading, growth, and migration, have been studied extensively to enhance cell-material interactions for both *in vivo* and *in vitro* applications [150, 151]. However, the effects observed for a given protein have been found to vary substantially depending on the nature of the underlying substrate and the method of immobilization [152, 153]. In biomaterial research there is a strong interest in new materials, which combine the required mechanical properties with improved biocompatibility. Instead of developing new biomaterials, surface coating or surface modification presents a way

to preserve the mechanical properties of established materials and to improve the surface biocompatibility [154]. A major objective in the design of fictionalized polymer surfaces for biomaterial applications is the attachment of proteins or peptides that promote integrin-mediated cell attachment. Most of the conventional materials do not meet the demands required for both their surface and bulk properties when used as biomaterials. An effective approach for developing a clinically applicable biomaterial is to modify the surface of a material, that already exhibits excellent biofunctionality and bulk properties.

Many materials used in surface engineering lack in reactive groups for the covalent attachment. For these materials the major challenge of surface engineering is the introduction of reactive groups to the surface. Methods of surface engineering and surface covalent attachment have been discussed in a number of excellent reviews [155]. These studies are of significance for future work on the surface engineering of scaffold and we note that they are establishing the initial stages of the application of biomimetics in the design and manufacture of tissue engineering scaffolds.

9. Conclusions and Future Directions for Tissue Engineering Scaffolds

Research in tissue engineering has revealed the design rules for joining cells with materials and for understanding the mechanism by which cellular functions can be influenced or interrogated by materials. Development of cell based microsystems outside tissue engineering will in the long term provide technologies that will be applied to tissue engineering. The technology developed to integrate the functions of cells with electrical or mechanical processes in materials will have important benefits to the growth of tissue for transplantation and for prosthetic interfaces between indwelling devices and natural tissue. Cell based engineering addresses the development of hybrid devices that combine cellular and tissue components with conventional materials and processes found in microfabrication. Research and development activities span a broad range of topics including technical development of methods and fabrication routes to join cells with materials, exploratory and discovery research to identify strategies for matching cellular processes with materials processes, and engineering of complete systems that exploit the unique realization that combining man made devices and biological systems.

Despite the advancements in the field of tissue engineering and scaffolds for tissue engineering, there are few challenges, which needs to be addressed. Various types of materials have been used for application in artificial implants or scaffolds can be broadly classified in to six categories namely, biotoxic, bioinert, biodegradable, bioresorbable and bioactive. Of these

most artificial implant materials either fall under the biotoxic (cadmium, vanadium, mercury used as dental amalgams) or the bioinert (tantalum, titanium etc.) categories while biodegradable, bioactive and bioresorbable materials are used in tissue engineering either singly or in combination or with bioinert materials depending on the application. The type of challenge varies with the material used for scaffolding application. Issues that needs to be addressed in temporary scaffolds using biodegradable polymers includes mechanical strength, toxicity of degradation products to the host tissue (If acidic polymer is used it may release acidic degradation products which is harmful to surrounding tissues), interconnected pore architecture for supply of nutrients upon cell seeding and smart control of degradation rate of the scaffold. Scaffolds fabricated of bioresorbable and naturally derived materials suffer from lack of mechanical strength and processability. Permanent scaffolds fabricated of metallic/ceramic materials can overcome the limitations with respect to strength and toxicity. Bioactive titanium meshes have been successfully used in spine fusion surgery for the past two decades. Most Tmesh cage uses autograft bones or femoral ring allograft for bone grafting. As explained earlier in this paper both the techniques have disadvantages such as complications during surgery, second site morbidity, infections in case of allografts and immunological rejections. Synthetic hydroxyapatite and coralline hydroxyapatite has been found to be a good alternative to autografts and allografts as they provide the necessary osteoconduction. However, the effect of pore morphology in the mesh and the mesh architecture has not been given a serious attention in the past. The stress shielding effect should be minimized if not eliminated by designing the mesh architecture, which would be conducive to osteoconduction in the presence of bioactive substances.

In the near term, a central challenge in these programs is the development of a common framework for designing and building structures having both materials and biological components. This framework must address the development of strategies to integrate the functions of engineered systems which are based on firm physics and engineering, use inorganic and metallic materials and are constructed with photolithography and micro-fabrication tools, with the functions of biological systems which use soft materials in aqueous environments, rely on self assembly for their construction and where the design rules are in many cases incompletely understood. Clearly, the field of tissue engineering needs to establish functional criteria that will help those who seek to design and manufacture these repairs and replacements. Scale-up, packaging, storage and handling properties are also critical. The implants must be capable of retaining their mechanical, structural, and biological integrity during surgical implantation. Understanding those conditions that preserve the character of the

implants may be essential for the success of the tissue-engineered products. It is important to consider the principles of functional tissue engineering in the light of the role of novel growth factors and new biomaterials.

References

1. Proceedings of the WTEC Workshop on Tissue Engineering Research in the United States, 175-178, 2000.
2. Babensee JE, Anderson JM. Host response to tissue engineered devices. *Advanced Drug Delivery Review* 1998; 33(1-2).
3. Perka C, Sittinger M. Tissue engineered cartilage repair using cryopreserved and noncryopreserved chondrocytes. *Clinical Orthopedics* 2000; 378: 245-254.
4. Anseth KS, Shastri VR. Photopolymerizable degradable polyanhydrides with osteocompatibility. *Nature Biotechnology* 1999; 17(2): 156-159.
5. Rachael H. Schmedlen, Kristyn S. Masters, Jennifer L. West. Photocrosslinkable polyvinyl alcohol hydrogels that can be modified with cell adhesion peptided for use in tissue engineering. *Biomaterials* 2002; 23: 4325-4332.
6. Kyati Truong Nguyen, Jennifer L. West. Photopolymerizable hydrogel for tissue engineering. *Biomaterials* 2002; 23: 4307-4314.
7. Amass W, Amass A. A review of biodegradable polymers: uses, current developments in the synthesis and characterization of biodegradable polyesters, blends of biodegradable polyesters, blends of biodegradable polymers and recent advances in biodegradation studies. *Polymer Int.* 1998; 47: 89-144.
8. Anderson JM, Langone JJ, Issues and perspectives on the biocompatibility and immunotoxicity evaluation of implanted controlled release systems. *Journal of Controlled Release* 1999; 57 (2): 107-113.
9. Peter S. Donzelli, Robert L. Spilker, Gerard A. Ateshian, Van C. Mow. Contact analysis of biphasic transversely isotropic cartilage layers and correlations with tissue failure. *J. Biomech.* 1999; 32(10); 1037-1047.
10. Badylak S, Amoczky S, Polouhar P, Haut R, Mendenhall V, Clarke R, Horvath C. Naturally occurring matrix as a scaffold for musculoskeletal repair. *Clinical Orthopedics* 1999; 367: S333-343.
11. Mow VC, Ratcliffe A, Poole AR. *Biomaterials* 1992; 13: 67-97.
12. Vunjak-Novakovixc G, Martin I, Obradovic B., et al, 1999, *J Orthop Res*, Vol. 17, pp. 130-138.
13. Hench LL, Polak JM, Xynos ID, Buttery LDK, Bioactive materials to control cell cycle, *Mat. Res. Innovat* 2000; 3: 313-323.
14. Hench. LL, Ethridge EC. *Biomaterials: An interfacial Approach*, 1982 Academic Press, New York.
15. Kwan MK, Coutts RD, Woo SL, Field FP. *J Biomech* 1989; 22: 921-930.
16. Komi PV, *J. Biomech.* 1990; 23: 23-44, Simon S. R., (Ed) (1994) *Orthopedic basic Science*, Am Acad Orthopedic Surgeons, Rosemong, IL.
17. Ham W.,(1969) *Histology*, J B Lippincot Co., Philadelphia.
18. Davies J. E., (Ed) (1991) *The Bone-Biomaterial interface*, University of Toronto Press.
19. atner B. D., Hoffman, A. S., Schoen, F. J., Lemons, J. E., (Eds) (2000), *Biomaterials Science* (2nd edition) Academic Press.
20. Chen, G., Ushida, T., & Tateishi, T. Scaffold Design for Tissue Engineering. *Macromolecular Bioscience*, 2002; 2(2): 67-77.
21. Chen, G., Ushida, T., & Tateishi, T. Development of Biodegradable Porous Scaffolds for Tissue Engineering. *Materials Science and Engineering C*, 2001; 17: 63-69.

22. Griffith LG, Polymeric biomaterials. *Acta Mater.* 2000; 48: 263-277.
23. Brannen CL, Sugaya K. In vitro differentiation of multipotent human neural progenitors in serum-free medium. *Neuroreport* 2000; 11(5): 1123-1128.
24. Taboas JM, Maddox RD, Krebsbach PH, Hollister SJ. Indirect solid free form fabrication of local and global porous, biomimetic and composite 3D polymer-ceramic scaffolds. *Biomaterials* 2003; 24: 181-194.
25. Hui PW, Leung PC, Sher A. Fluid conductance of cancellous bone graft as a predictor for graft-host interface healing. *J. Biomech* 1996; 1: 123-132.
26. Kuboki Y, Takita H, Kobayashi D, Tsuruga E Inoue M, Murata M, Nagai, N, Dohi Y, Ogushi H, BMP induced osteogenesis on the surface of hydroxyapatite with geometrically feasible and non-feasible structures: topology of osteogenesis. *J Biomed Mater Res.* 1998; 39(2): 190-199.
27. Blokhuis TJMD, Termaat MFMD, den Boer FCMD, Patka PMDP, Bakker FCMDP, Haarman HJTMMDP. Properties of calcium phosphate ceramics in relation to their in vivo behaviour. *J Traum Inj Inf Crit Care* 2000; 48(1): 17.
28. Zeltinger J, Sherwood JK, Graham DA, Mueller R, Griffith LG, Effect of pore size and void fraction of cellular adhesion, proliferation, and matrix deposition. *Tissue Eng.* 2001; 7(5): 557-572.
29. Freyman TM, Yannas IV, Gibson LJ, Cellular materials as porous scaffolds for tissue engineering. *Prog Mater Sci.* 2001; 46(3-4): 273-282.
30. Cima LG, Vacanti JP, Vacanti C, Ingber D, Mooney D, Langer R, Tissue engineering by cell transplantation using degradable polymer substrates. *J Biomech Eng. ASME* 1991; 113(2): 143-151.
31. Holmes RE, Bucholz RW, Mooney V. Porous hydroxyapatite as a bone-graft substitute in metaphyseal defects-a histometric study. *J Bone Jt Surg Am.* 1986; 68A(6): 904-911.
32. Gauthier O, Bouler JM, Aguado E, Pilet P, Daculsi G, Macroporous biphasic calcium phosphate ceramics; influence of macropore diameter and macroporosity percentage on bone ingrowth. *Biomaterials* 1998;19(1-3): 133-139.
33. Shors EC, Coralline bone graft substitutes, *Orthop Clin North Am.* 1999; 30 (4): 599-613.
34. Tsuruga E, Takita H, Itoh H, Wakisaka Y, Kuboki, Y, Pore size of porous hydroxyapatite as the cell substratum controls BMP induced osteogenesis, *J Biochem.* 1997; 12(2): 317-324.
35. Le Huec J, Schavereke T, Clement D, Faber J, Le Rebeller A, Influence of porosity on the mechanical properties of coralline hydroxyapatite ceramics under compressive stress. *Biomaterials* 1995; 16(2): 113-118.
36. Martin RB, Chapman MW, Sharkey NA, Zissimos SL, Bay B, Shors EC, Bone ingrowth and mechanical properties of coralline hydroxyapatite 1 year after implantation. *Biomaterials* 1993; 14(5): 341-348.
37. Coombes AGA, Heckman JD, Gel casting of resorbable polymers: Processing and applications. *Biomaterials* 1992; 13(4): 217-224.
38. Thomson RC, Yaszemski MJ, Powere JM, Mikos AG, Fabrication of biodegradable polymer scaffolds to engineer trabecular bone. *J. Biomater Sci Polym.* Ed 1995; 7(1) 23-28.
39. Liao CJ, Chen CF, Chen JH, Chiang SF, Lin YJ, Chang KY, Fabrication of porous biodegradable polymer scaffolds using a solvent merging/particulate leaching method, *J Biomed Mater Res.* 2002; 59 (4): 676-681.
40. Ma PX, Choi JW, Biodegradable polymer scaffolds with well-defined interconnected spherical pore network. *Tissue Eng.* 2001; 7(1): 23-33.
41. Whang K, Thomas CH, Healy KE, Nuber G. A novel method to fabricate bioabsorbable scaffolds. *Polymer* 1995; 36(4): 837-842.
42. Schugens C, Granfils C, Jerome R, Teyssie P, Delree P, Martin D, Malgrange B, Moonen G, Preparation of a macroporous biodegradable polylactide implant for neural transplantation, *J Biomed Mater Res.* 1995; 29(11): 1349-1362.
43. Niwa T, Takeuchi H, Hino T, Kunou N, Kawashima Y, In vitro drug release behavior of D, L-lactide/glycolide copolymer (PLGA) nanospheres with nafarelin acetate prepared by a novel spontaneous emulsification solvent diffusion method, *J Pharm Sci.* 1994; 83(5): 727-732.
44. Bruder SP, Kraus KH, Goldberg VM, Kadiyala S, Critical-sized canine segmental femoral defects are healed by autologous mesenchymal stem cell therapy, In the 44th annual Meeting of the


- Orthopedic Research Society, March 16-19, New Orleans, LA, Orthopedic research Society, 1998, 147.
45. Hadlock T, Sundback C, Hunter D, Cheney M, Vacanti JP, A polymer foam conduit seeded with Schwann cells promotes guided peripheral nerve regeneration, *Tissue Eng.* 2000; 6(2): 119-127.
 46. Freed LE, Vunjak-Novakovic G, Biron RJ, Eagles DB, Lesnoy DC Barlow SK, Langer R, Biodegradable polymer scaffolds for tissue engineering. *Biotechnology* 1994; 12(7): 689-693.
 47. Le Hues J, Schaevereke T, Clement D, Faber J, Le Rebeller A, Influence of porosity on the mechanical resistance of hydroxyapatite ceramics under compressive stress. *Biomaterials* 1995; 16(2): 113-118.
 48. Wu BM, Borland SW, Giordano RA, Cima LG, Sachs EM, Cima MJ, Solid free-form fabrication of drug delivery devices. *J Control Rel.* 1996; 40(1-2): 77-87.
 49. Zhang R, Ma PX, Synthetic nano- fibrillar extracellular matrices with predesigned macroporous architectures. *J. Biomed Mater Res.* 2000; 52(2): 430-438.
 50. Brocchini S, James KV, Tangpasuthadol J, Kohn J. *Biomedical Mater. Res.* 1998; 42: 66-75.
 51. Hutmacher DW. Scaffolds in tissue engineering bone and cartilage. *Biomaterials* 2000; 21(24): 2529-2543.
 52. Widmer MS, Gupta PK, Lu L, Meszlenyi RK, Evans GR, Brandt K, Savel T, Gurlek A, Patrick Jr CW, Mikos AG. Manufacture of porous biodegradable polymer conduits by an extrusion process guided tissue regeneration. *Biomaterials* 1998; 19(21): 1945-1955.
 53. Zein, I, Hutmacher DW, Tan KC, Teoh SH. Fused deposition modeling of novel scaffold architectures for tissue engineering applications. *Biomaterials* 2002; 23(4): 1169-1185.
 54. Hutmacher DW, Schantz T, Zein I, Ng KW, Teoh SH, Tan KC. Mechanical properties and cell cultural response of polycaprolactone scaffolds designed and fabricated by using fused deposition modeling. *J Biomed Mater Res.* 2001; 55(2): 203-216.
 55. Rimell JT, Marquis PM. Selective laser sintering of ultra high molecular weight polyethylene for clinical applications, *J Biomed Mater Res.* 2000; 55(4): 414-420.
 56. Vail NK, Swain LD, Fox WC, Aufdemorte TB, Lee G, Barlow JW. Materials for biomedical applications. *Mater Des.* 1999; 29(2-3): 23-32.
 57. Stoodley MA, Abbott JR, Simpso DA. Titanium cranioplasty using 3-D computer modeling of skulls detects. *J Clin Neurosci.* 1996; 3(2): 49-55.
 58. Shishkovsky IV, Tarasova EY, Zhuravel LV, Petrov AL. The synthesis of a biocomposite based on nickel titanium and hydroxyapatite under selective laser sintering conditions. *Tech Phys Lett.* 2001; 27(3): 211-213.
 59. Lu SX, Ramirez WF, Anseth KS, Modeling and optimization of drug release from laminated polymer matrix devices. *AIChE J.* 1998; 44(7): 1689-1696.
 60. Levy RA, Chu TMG, Halloran JW, Feinberg SE, Hollister S, CT-generated porous hydroxyapatite orbital floor prosthesis as a prototype bioimplant. *Am J Neuroradiol.* 1997; 18(8): 1522-1555.
 61. Porter NL, Pillaiar RM, Grynblas MD, Fabrication of porous calcium polyphosphate implants by solid free form fabrication: a study of processing parameters and in vitro degradation characteristics. *J Biomed Mater Res.* 2001; 56(4): 504-515.
 62. Curodeau A, Sachs E, Caldarise S, Design and fabrication of cast orthopedic implants by solid free form surface textures from 3-D printed ceramic shell. *J Biomed Mater Res.* 2000; 53(5): 525-535.
 63. Hong SB, Eliaz N, Leisk GG, Sachs EM, Latanision RM, Allen SM, A new Ti-5Ag alloy for customized prostheses by three-dimensional printing (3DP(TM)). *J Dent Res.* 2001; 80(3): 860-863.
 64. Dutt Roy J, Patterson J, Chesmel K, Payumo F, Doshi A, Choi J, Parsons J, An in vivo analysis of bone repair products made by three-dimensional fabrication techniques. In: *The 47th Annual Meeting of the Orthopedic Research Society, February 25-28, San Francisco, Orthopedic Research Society, 2001, 0196.*
 65. Kreklau B, Sittinger M, Mensing M, Voigt C, Berger G, Burmester G, Rahmzadeh R, Gross U. Tissue engineering of biphasic joint cartilage transplants. *Biomaterials.* 1999; 20: 1744-1740.
 66. Murphy WL, Kohn DH, Mooney DJ, Growth of continuous bonelike mineral within porous poly(lactide-co-glycolide) scaffolds in vitro. *J Biomed Mater Res.* 2000; 50(1): 50-58.
 67. Bigi A, Boanini E, Panzavolta S, Roveri N, Rubini K, Bonelike apatite growth on hydroxyapatite-gelatin sponges from simulated body fluid. *J Biomed Mater Res.* 2002; 59(4): 709-715.

68. Ball MD, Howdle SM, Antonov EN, Bagratashvili VN, Popov VK, Sobol EN, Downes S. Hydroxyapatite coating of biodegradable polymers by pulsed laser deposition. *J Bone Jt Surg Br*. 1998; 80B (3S): 258.
69. Ylimen P, Kinnunen J, Laasonen E M, Lamminen A, Vainionpää S, Raekallio M, Rokkanen P, Tormala P, Lumbar spine interbody fusion with reinforced hydroxyapatite implants. *Arch Orthop Trauma Surg*. 1991; 110(5): 250-256.
70. Tencer AF, Woodard PL, Swenson J, Brown KL, Bone ingrowth into polymer coated porous synthetic coralline hydroxyapatite., *J Orthop Res*. 1987; 5(2): 275-282.
71. Ignjatovic N, Tomic S, Kakic M, Miljkovic M, Plavsic M, Uskokovic D, Synthesis and properties of hydroxyapatite /polyL-lactide composite biomaterials. *Biomaterials*. 1999; 20: 809-816.
72. Kasuga T, Osa Y, Masayuki N, Abe Y, Preparation and mechanical properties of polylactic acid composites containing hydroxyapatite fibers. *Biomaterials*. 2001; 22(1): 19-23.
73. Durucan C, Brown PW, Low temperature formula of calcium-deficient hydroxyapatite-PLA/PLGA composites. *J Biomed Mater Res*. 2000; 51(4): 717-725.
74. Shikami Y, Okuno M, Bioresorbable devices made of forged composites of hydroxyapatite (HA) particles and poly L-lactide (PLLA): Part I, Basic characteristics. *Biomaterials*. 1999; 20(9): 859-877.
75. Deng X, Hao J, Wang C, Preparation and mechanical properties of nanocomposites of poly (D, L-lactide) with Ca-deficient hydroxyapatite nanocrystals. *Biomaterials*. 2001; 22(21): 2867-2873.
76. Mikos A, Sarakinos G, Vacanti J, Langer R, Cima L, Biocompatible polymer membranes and methods of preparation of three dimensional membrane structures. US patent No. 5514378, 1996.
77. Zhang R, Ma P, poly(alpha-hydroxyl acid) hydroxyapatite porous composites for bone-tissue engineering, In: Preparation and morphology. *J Biomed Mater Res*. 1994; 44(4): 46-455.
78. Devin JE, Attawia MA, Laurencin CT, Three-dimensional degradable porous polymer-ceramic matrices for use in bone repair. *J Biomater Sci Polym*. Ed 1996, 7 (8) 661-669.
79. Verheyen C, Klein C, de-Blieck-Hogervorst J, Wolke J, vanBlitterswijk, deGroot K, Evaluation of hydroxyapatite/poly(L-lactide) composites: physico-chemical properties. *J Mater Sci Mater Med*. 1993; 4(1): 58-65.
80. Minamide AMD, Tamaki TMDP, Kawakami MMDP, Hashizume HMDP, Yoshida MMDP, Sakata RMD. Experimental spinal fusion using sintered bovine bone coated with type I collagen and recombinant human bone morphogenetic protein-2. *Spine*. 1999; 24(18): 1863.
81. Chapman MW, Bucholz R, Cornell C. Treatment of acute fractures with a collagen-calcium phosphate graft material-a randomized clinical trial. *J Bone Jt Surg Am*. 1997; 79A (4): 485-502.
82. Rhee SH, Tanaka J. Synthesis of a hydroxyapatite/collagen/chondroitin sulfate nanocomposite by a novel precipitation method. *J Am Ceram Soc*. 2001; 84 (2): 459-461.
83. Kikuchi M, Suetsugu Y, Tanaka J, Akao M. Preparation and mechanical properties of calcium phosphate/copoly L-lactide composites. *J Mater Sci: Mater Med*. 1997; 8(6): 361-364.
84. Hench LL, West JK. Biological Applications of Bioactive Glasses. *Life Chemistry Reports* 1996; 13: 187-241.
85. Black J. *Biomaterials* 5-11, Revell. P., (1986) Pathology of Bone, Springer-Verlaag, Berlin. 1984.
86. Hench LL, Splinter RJ, Allen WC, Greenlee TK, J. *Biomed Mater Res*. 1971; 2: 117.
87. Wilson J, Low SB. *J Appl Biomaterials*. 1992; 3: 123.
88. Malaviya P, Butler DL, Korvick DL, Proch FS, *J Biomech*. 1998; 31: 1043-1049.
89. Fetner AE, Hartigan MS, Low SB, 1994 Compendium Contin Educ Dent, 15:932, Shors, E. C., Holmes R. E (1993) Porous hydroxyapatite. In: Hench LL, Wilson J. (Eds) *An Introduction to Bioceramics*, World Scientific, UK, p181
90. Hench LL, Clark AE, (1982) Adhesion to Bone. In: Williams DF (Ed) *Biocompatibility of Orthopedic Implants*, Vol. 2, Boca Raton, FL.
91. Han DK, Hubbell JA. Lactide-based poly(ethylene glycol) polymer networks for scaffolds in tissue engineering. *Macromolecules* 1996; 29(15): 5233-5235.
92. Wilson J, Clark A E, Douek E, Krieger J, Smith WK, Zimet JS, (1994) Clinical Applications of Bioglass Implants, In: *Bioceramics* 7, Anderson, Happonen, Yli-Urpo(Eds), Butterworth-Heinemann, Oxford.
93. Matsuda T, Davice JE., (1987) *Biomaterials* 8:275, Vrouwenveldr, W. C. A., Groot, C. G., de Groot, K., (1992) *Biomaterials* 13:382.
94. Price N, Bendall SP, Frondosa C, Jinnah RH, Hungerford D, *J Biomed Mater Res*. 1997; 37: 394.


95. Butler D, Goldstein SA, Guilak F. *J. Biomech Engg.* 2000; 122.
96. Keeting PE, Oursler MJ, Wiegand KE, Bonde SK, Spelsberg TC, Riggs BL, *J. Bone Miner Res.* 1992; 7: 1281.
97. El-Ghannam A, Ducheyne P, Shapiro IM, *J Biomed Mater Res.* 1995; 29: 359.
98. Pego AP, Poot AA, Copolymers of trimethylene carbonate and epsilon-caprolactone for porous nerve guides:synthesis and properties. *J. Biomater.Sci. Polym. Ed* 12, (2001) 35-53
99. El Ghannam A, Ducheyne P, Shapiro IM, Effect of serum proteins on osteoblast adhesion to surface –modified bioactive glass and hydroxyapatite, *J Orthop Res.* 1999; 17: 40-45.
100. Atala A., Bauer SB, Hendren WH, Retik AB, The effect of gastric augmentation on bladder function. *J Urol* 1993; 149: 1099-1102.
101. Draper WJ, Stark RB, End Results in the replacement of mucous membrane on the urinary bladder with thick-split grafts of skin, *Surgery* 1956; 39: 434-440.
102. Hutschenreiter G, Rumpelt HJ, Klippel KF, Hohenfellner R, The free peritoneal transplant as a substitute for the urinary bladder wall. *Invest Urol.* 1978; 15: 375-379.
103. Neuhoef H. Fascia transplantation into visceral defects. *Surg Gynecol Obstet.* 1917; 14: 383-427.
104. Goldstein MB, Dearden LC, Gualtieri V, Regeneration of subtotally cystectomized bladder patched with omentum: an experimental study in rabbits. *J Urol.* 1967; 97: 664-668.
105. Henly DR, Barret DM, Welland TL, Particulate silicon for use in periurethral injections: local tissue effects and search for migration. *J. Urol.* 1995; 153: 2039-2043.
106. Bazeed MA, Thuroff JW, Schmidt RA, Tanagho EA, New treatment for urethral strictures. *Urology* 1983; 21: 53-57.
107. Li St, 1995, *Biologis biomaterials; tissue derived biomaterials (collagen)* In: Brozino J D (Ed) *The biomedical engineering handbook* CRC, Boca Raton, Florida 627-647.
108. Furthmayr H, Timpl R , *Immunochemistry of collagens and procollagens*, *Int Rev Connect Tissue Res.* 1976; 7: 61.
109. Pachence JM, Collagen based devices for soft tissue repair. *J Biomed Mater Res Appl Biomater.* 1996; 33: 35-40.
110. Byung-Soo Kim, Carlos E. Baez, Anthony Atala, *Biomaterials for tissue engineering*, *Worl J Urol.* 2000; 18: 2-9.
111. Hendren WH, Reda EF, Bladder mucosa graft for construction of male urethra *J. Pediatr Surg.* 1986; 21: 189-192.
112. Silver FH, Pins G, Cell growth on collagen: a review of tissue engineering using scaffolds containing extracellular matrix. *J Long-term Effects Med Implants* 1992; 2: 67-80.
113. Sam AE, Nixon AJ, Chondrocyte-laden collagen scaffolds for resurfacing extensive articular cartilage defects. *Osteoarthritis Cartilage* 1995; 3: 47-59.
114. Smidsrod O, Skjak-Braek G, Alginate as an immobilization matrix for cells *Trends Biotech* 1990; 8: 71-78.
115. Rowley JA, Madlambayan G, Mooney DJ, Alginate hydrogels as synthetic extracellular matrix materials, *Biomaterials* 1999; 20: 45-53.
116. Chen F, Yoo JJ, Atala A, Acellular collagen matrix as a possible “off the shelf” biomaterial for urethral repair. *Urology* 1999; 54: 407-410.
117. Probst M, Dahiya R, Carrier S, Tanagho E A, Reproduction of functional smooth muscle tissue and partial bladder replacement. *Br J Urol.* 1997; 79: 505-515.
118. Dahms SE, Piechota HJ, Dahiya R, Lue TF, Tanagho EA, Composition and biochemical properties of the bladder acellular matrix graft: comparative analysis in rat, pig and human. *Br J Urol.* 1998; 82: 41-419.
119. Kulkarni RK, Moore EG, et al. *Biodegradable poly (lactic acid) polymers.*, *J. Biomed. Mat. Res.* 1971; 5: 169-181.
120. Gregory H. Altman, Frank Diaz, Caroline Jakuba, Tara Calabro, Rebecca L. Horan, Jingsong Chen, Helen Lu, John Richmond and David L. Kaplan, Silk-based biomaterials, *Biomaterials* 2003; 24(3): 401-416.
121. Angela S P. Lina, Thomas H. Barrowsb, Sarah H. Cartmella, Robert E. Guldberg, Microarchitectural and mechanical characterization of oriented porous polymer scaffolds, *Biomaterials* 2001; 24(3): 481-489.
122. Graham NB, *Hydrogels: their future*, Part I, *Med Device Thechnol*, 1998, 9, 18-22
123. Graham N B, *Hydrogels: Part II*, *Med Device Technol*, 1998, 9, 22-25.

124. Peppas NA, Hydrogen in medicine and pharmacy, Florida: CRC Press, 1987, Peppas N A, Bures, P, Hydrogels in pharmaceutical formulations, *Eur J Pharm Biopharm* 2000; 50:27-46.
125. Hill-West JL, Dunn RC, Local release of fibrinolytic agents for adhesion prevention, *J Surg Res.* 1995, 59, 759-763
126. Chowdhury, S M, Hubbel J A, Adhesion prevention with anicrod released via a tissue-adherent hydrogel, *J surg Res.* 1996, 61, 81-87.
127. Russel RJ, Pishko MV, A fluorescence-based glucose biosensor using concanavalin A and dextran encapsulated in a poly(ethylene glycol) hydrogel, *Anal Chem* 1999; 71: 3126-3132.
128. Pathak CP, Sawheney AS, Rapid photopolymerization of immunoprotective gels in contact with cells and tissue, *J Am Chem Soc.* 1992; 114: 8311-8312.
129. Cruise GM, Hegre OD, In vitro and in vivo performance of porcine islets encapsulated in interfacially photopolymerized poly(ethylene glycol) diacrylate membranes, *Cell Transplant* 1999; 8: 293-306.
130. Suggs LJ, Mikos AG, Development of poly(propylene fumarate-co-ethylene glycol) as an injectable carrier for endothelial cells, *Cell Transplant*, 1999; 8: 345-350.
131. Suggs LJ, Mikos AG, Development of poly(propylene fumarate-co-ethylene glycol) as an injectable carrier for endothelial cells, *Cell Transplant*, 1999; 8: 345-350.
132. Mann BK, Gobin AS, Smooth muscle cell growth in photopolymerized hydrogels with cell adhesive and proteolytically degradable domains: synthetic ECM analogs for tissue engineering, *Biomaterials* 2001; 22: 3045-3051.
133. Kyati Truong Nguyen, Jennifer L. West, Photopolymerizable hydrogels for tissue engineering applications, *Biomaterials* 2002; 23: 4307-4314.
134. Masatoshi Sato, Mutuhiro Maeda, Hisashi Kurosawa, Yukio Lnoe, Yasuo Yamauchi, Reconstruction of rabbit Achilles tendon with three bioabsorbable materials: histological and biomechanical studies, *J Orthop Sci*, 2000; 5: 256-267.
135. Tan, J., & Saltzman, M. Topographical control of human neutrophil motility on micropatterned material with various surface chemistry. *Biomaterials*, 2002, 23: 3215-3225.
136. Altman, G.H., Diaz, F., Jakuba, C., & Calabro et al. Silk-based Biomaterials. *Biomaterials*. 2002, 24: 401-416.
137. Peter D. Waite, and Jack E. Lemons, " Strength Analysis of Le Fort I Osteotomy Fixation: Titanium Versus resorbable Plates", *J Oral Maxillofac Surg*, 2001, 59:1034-1039.
138. A.L. Bhat, G.L. Lowery, A. Sei, The use of titanium surgical mesh bone graft composite in the anterior thoracic or lumbar spine after complete or partial corpectomy, *Eur Spine J*, 1999, 8 (4) 304-309.
139. V.K. Panchbhavia, S.G. Trevino, "Use of titanium cages with cancellous bone graft in hind foot fusion: literature review and case reports with complications", *Foot and Ankle Surgery*, 2003, 9 51-55.
140. John S. Thalgott, James M. Giuffre, Zendek Klezl, Marcus Timlin, "Anterior lumbar interbody fusion with titanium mesh cages, coralline hydroxyapatite, and demineralized bone matrix as part of a circumferential fusion" *The Spine Journal*, 2002, 2: 63-69.
141. Ching-hsin Ku, D.P. Pioletti, M. Browne and P.J. Gregson, "Effect of different Ti-6Al-4V surface treatments on osteoblasts behaviour", *Biomaterials*, 2002, 23: 1447-1454.
142. M. bigerelle, K. Anselme, B.Noel, I. Ruderman, P.Hardouin and A. Iost, "Improvement in the morphology of Ti-based surfaces: a new process to increase in vitro human osteoblast response", *Biomaterials*, 2002, 23: 1563-1577.
143. L.N. Ramoshebi, T.N. Matsaba, J.Teare, L. Renton, J. Patton and U Ripamonti, "Tissue engineering: TGF- β superfamily members and delivery systems in bone regeneration", *Expert Reviews in Molecular Medicine*, 2002: 1-11.
144. R. Lange, F.Luthen, U.Beck, J.Rychly, A. Baumann and B. Nebe, "Cell-extracellular matrix interaction and physico-chemical characteristics of titanium surfaces depend on the roughness of the material", *Biomolecular Engineering*, 2002, 19: 255-261.
145. E. Eisenbarth, J. Meyle, W. Nachtigall and J. Breme, "Influence of the surface structure of titanium materials on the adhesion of fibroblasts", *Biomaterials*, 1996, 17:1399-1403.
146. M. Todd Brandt and R.H. Hang, "The use of a polyurethane skull replica as a template for contouring titanium mesh", *Journal of Oral Maxillofac Surg*, 2002, 60:337-338.

147. Z. Xiong, Y. Yan, S. Wang, R. Zhang and C. Zhang, "Fabrication of porous scaffolds for bone tissue engineering via low-temperature deposition", *Scripta Materialia*, 2002, 46: 771-776.
148. M.E. Gomes, A.S. Ribeiro, P.B. Malafaya, R.L. Reis and A.M. Cunha, "A new approach based on injection moulding to produce biodegradable starch-based polymeric scaffolds: morphology, mechanical and degradation behaviour", *Biomaterials*, 2001, 22: 883-889.
149. M.E. Gomes, J.S. Godinho, D. Tchalamov, A.M. Cunha and R.L. Reis, "Alternative tissue engineering scaffolds based on starch: processing methodologies, morphology, degradation and mechanical properties", *Material Science and Engineering C*, 2002, 20:19-26.
150. Altman, G.H., Diaz, F., Jakuba, C., & Calabro et al. Silk-based Biomaterials. *Biomaterials*. 2002, 24: 401-416.
151. Kobayashi, H., Ikada, Y. Corneal cell adhesion and proliferation on hydrogel sheets bound with cell adhesive proteins. *Curr Eye Res*. 1991, 10: 899-908.
152. Anselme, K. Osteoblast adhesion to materials. *Biomaterials*. 2000, 21: 667-81.
153. Neff, J. A., Tresco, P. A. and Cadwell K. D. Surface modification for controlled studies of cell-ligand interaction. *Biomaterials*. 1991, 20: 2377-93.
154. Juliano D. J., Saaedra, S. S. and Truskey, G. A. Effect of the conformation and orientation of adsorbed fibronectin on endothelial cell spreading and the strength of adhesion. *J. Biomed. Mater Res.*, 1993, 27: 1103-11.
155. Hoffman, A. S., Biologically functional materials. In: Ratner BD, Hoffman AS, Shoen JE, editors, *Biomaterials science: an introduction to materials in Medicine*. 1996. New York: Academic Press, 1996. pp. 124-30.
156. K.H. Tan, C.K.Chua, K.F. Leong, C.M. Cheah, P.Cheang, M.S. Abu baker, and S.W. Cha, "Scaffold development using selective laser sintering of polyetheretherketone – hydroxyapatite biocomposite blends", *Biomaterials*, 2003, 24: 3115-3123.
157. E. Sachlos, N. Reis, C. Ainsley, B.Derby and J.T. Czernuszka, "Novel collagen scaffolds with predefined internal morphology made by solid freeform fabrication", *Biomaterials*, 2003, 24:1487-1497.
158. Y. Li, T. Ma, S.T. Yang and D.A. Kniss, "Thermal compression and characterization of 3-D non-woven PET matrices as tissue engineering scaffold", *Biomaterials*, 2001, 22: 609-618.
159. Y. Yan, Z. Xiong, Y.Hu, S. Wang, R. Zhang and C. Zhang, "Layered manufacturing of tissue engineering scaffolds via multi-nozzle deposition", *Material Letters*, 2003 [In Press]
160. T.H. Ang, F.S.A. Sultana, D.W.Hutmacher, Y.S. Wong, J.Y.H. Fuh, X.M. Mo, H.T. Loh, E. Burdet and S.H. Teoh, "Fabrication of eD chitosan-hydroxyapatite scaffolds using a robot dispensing system", *Materials Science & Engineering C*, 2002, 20: 35-42.
161. H. Yoshimoto, Y.M. Shin, H.Terai and J.P. Vacanti, "A biodegradable nanofiber scaffold by electrospinning and its potential for none tissue engineering", *Biomaterials*, 2003, 24: 2077-2082.



(a) SEM picture of bovine Collagen scaffold
(courtesy Dr. Philip Cheang,/Dr. Ma NTU)





(b) Confocal microscope image of PGA scaffold

Fig. 1 Microscopic Images of Scaffolds



(a) Bioglass implants/scaffolds : Courtesy Dr. Philip Cheang, NTU



(b) Biocomposites using synthetic polymer and HA for scaffold applications: Coutesy Dr. Philip Cheang, NTU

Fig. 2 Examples of Natural and Synthetic scaffolds